4/A: Sana Biotechnology Director Hans Edgar Bishop Corrects Stock Option Acquisition in Amended SEC Filing
SEC Filing
Hans Edgar Bishop, a director at Sana Biotechnology, files an amended SEC Form 4 to correct the number of stock options acquired.
Summary
- Hans Edgar Bishop, a director of Sana Biotechnology, Inc., filed an amended Form 4 with the SEC.
- The amendment corrects a clerical error regarding the number of option shares acquired on June 6, 2024.
- Bishop acquired 65,000 stock options with an exercise price of $7.36.
- The options vest and become exercisable as to 100% of the underlying shares on the earlier of June 6, 2025, or immediately prior to the 2025 annual meeting of stockholders, contingent upon continuous service to Sana Biotechnology, Inc.
Sentiment
Score: 5
Explanation: The document is a routine regulatory filing correcting a clerical error. It doesn't contain information that would significantly impact investor sentiment positively or negatively.
Industry Context
This filing is a routine disclosure related to insider transactions, which are common in publicly traded companies like Sana Biotechnology. It provides transparency to investors regarding the compensation and holdings of company directors.
Key Dates
| Date | Description |
|---|---|
| 06/06/2024 | Date of stock option acquisition |
| 06/07/2024 | Date of original filing |
| 06/06/2025 | Earliest date for option vesting |
| 07/15/2024 | Date of amended filing |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.